179 related articles for article (PubMed ID: 23506208)
21. [Glycopyrronium bromide is a long-acting inhaled anticholinergic in the treatment of severe COPD].
Ulrik CS
Ugeskr Laeger; 2013 Aug; 175(35):1946-8. PubMed ID: 23978116
[TBL] [Abstract][Full Text] [Related]
22. Budesonide/Glycopyrronium/Formoterol: A Review in COPD.
Heo YA
Drugs; 2021 Aug; 81(12):1411-1422. PubMed ID: 34342835
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.
Wang C; Sun T; Huang Y; Humphries M; Bai L; Li L; Wang Q; Kho P; Firth R; D'Andrea P
Int J Chron Obstruct Pulmon Dis; 2015; 10():57-68. PubMed ID: 25609940
[TBL] [Abstract][Full Text] [Related]
24. Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model.
Trifilieff A; Ethell BT; Sykes DA; Watson KJ; Collingwood S; Charlton SJ; Kent TC
Toxicol Appl Pharmacol; 2015 Aug; 287(1):9-16. PubMed ID: 26026369
[TBL] [Abstract][Full Text] [Related]
25. Randomized study of the effects of Aerochamber Plus
Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
[TBL] [Abstract][Full Text] [Related]
26. In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models.
Pulido-Rios MT; McNamara A; Obedencio GP; Ji Y; Jaw-Tsai S; Martin WJ; Hegde SS
J Pharmacol Exp Ther; 2013 Aug; 346(2):241-50. PubMed ID: 23685545
[TBL] [Abstract][Full Text] [Related]
27. Combination therapy with indacaterol and glycopyrronium bromide in the management of COPD: an update on the evidence for efficacy and safety.
Ridolo E; Montagni M; Riario-Sforza GG; Baroni M; Incorvaia C
Ther Adv Respir Dis; 2015 Apr; 9(2):49-55. PubMed ID: 25691493
[TBL] [Abstract][Full Text] [Related]
28. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease.
Vogelmeier C; Banerji D
Ther Adv Respir Dis; 2011 Jun; 5(3):163-73. PubMed ID: 21511677
[TBL] [Abstract][Full Text] [Related]
29. [The combination of indacaterol and glycopyrronium has effects on symptoms, lung function, and rate of exacerbations in COPD patients].
Ulrik CS
Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294211
[TBL] [Abstract][Full Text] [Related]
30. Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study.
Rogliani P; Ora J; Puxeddu E; Calzetta L; Cavalli F; Matera MG; Cazzola M
Pulm Pharmacol Ther; 2018 Apr; 49():20-26. PubMed ID: 29294360
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects.
Reisner C; Miller J; DePetrillo P; Maes A; Siddiqui S; Martin UJ
Pulm Pharmacol Ther; 2018 Dec; 53():33-38. PubMed ID: 30218695
[TBL] [Abstract][Full Text] [Related]
32. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
Beeh KM; Singh D; Di Scala L; Drollmann A
Int J Chron Obstruct Pulmon Dis; 2012; 7():503-13. PubMed ID: 22973092
[TBL] [Abstract][Full Text] [Related]
33. The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium.
Sykes DA; Dowling MR; Leighton-Davies J; Kent TC; Fawcett L; Renard E; Trifilieff A; Charlton SJ
J Pharmacol Exp Ther; 2012 Nov; 343(2):520-8. PubMed ID: 22854200
[TBL] [Abstract][Full Text] [Related]
34. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
[TBL] [Abstract][Full Text] [Related]
35. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA; Banerji D; Chapman KR; Vestbo J; Roche N; Ayers RT; Thach C; Fogel R; Patalano F; Vogelmeier CF;
N Engl J Med; 2016 Jun; 374(23):2222-34. PubMed ID: 27181606
[TBL] [Abstract][Full Text] [Related]
36. Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.
D'Urzo AD; Kerwin EM; Chapman KR; Decramer M; DiGiovanni R; D'Andrea P; Hu H; Goyal P; Altman P
Int J Chron Obstruct Pulmon Dis; 2015; 10():1599-612. PubMed ID: 26316734
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.
Vincken W; Aumann J; Chen H; Henley M; McBryan D; Goyal P
Int J Chron Obstruct Pulmon Dis; 2014; 9():215-28. PubMed ID: 24596459
[TBL] [Abstract][Full Text] [Related]
38. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
Horita N; Kaneko T
Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
[TBL] [Abstract][Full Text] [Related]
39. A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.
Chiu MH; Al-Majed NS; Stubbins R; Pollmann D; Sandhu RK
BMC Res Notes; 2016 Jun; 9():310. PubMed ID: 27301406
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and Tolerability of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate and Glycopyrronium/Formoterol Fumarate Dihydrate Metered Dose Inhalers in Healthy Chinese Adults: A Randomized, Double-blind, Parallel-group Study.
Chen Q; Hu C; Yu H; Shen K; Assam PN; Gillen M; Liu Y; Dorinsky P
Clin Ther; 2019 May; 41(5):897-909.e1. PubMed ID: 30982547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
